Home 
ASAQ (Malaria) Implementation
ASAQ (Malaria) Implementation
Implementation
ASAQ registered in 30 African countries and India More than 120 million treatments distributed  Click on the map to enlarge and see countries were ASAQ is registered |
| |||||||||||||||
| ASAQ is registered in: | ||||||||||||||||
 Angola Benin Burundi Burkina Faso Cameroon Central African Republic Congo Ivory Coast DRC | Gabon Ghana Guinea India Kenya Liberia Madagascar Mali Mauritania Marocco | Mozambique Niger Nigeria Senegal South Sudan Chad Tanzania Togo Uganda | ||||||||||||||
| Registration In February 2007, ASAQ was registered in Marocco, the country of manufacturing of the medicine, a decisive step which enabled rapid exportation to other African countries. In October 2008, the WHO granted ASAQ a "pre-qualified" status. Registration applications were submitted in 30 malaria-endemic African countries and approval were obtained in 28 of them between November 2006 and September 2010. ASAQ was also registered in India in 2010. Field Monitoring Programme DNDi, Sanofi and additional partners, in particular MMV and National Malaria Control Programmes, are implementing a comprehensive “ASAQ Field Monitoring Programme” that aims to collect high-quality data on ASAQ effectiveness and safety profile in “the field”. This programme includes a series of proactive clinical studies conducted in several countries of sub-Saharan Africa with different levels of disease transmission. Key ongoing studies include two post-registration studies being done in collaboration with MSF, Epicentre, and the National Malaria Control Programme in Liberia. In Ivory Coast, two clinical studies are being set up in collaboration between Sanofi, MMV, and DNDi. Ultimately, more than 20,000 patients will be followed as part of this monitoring plan. Market and policy surveys DNDi, in collaboration with African researchers and national malaria control programmes, assessed in 2009 the market of antimalarials in Burundi and Sierra Leone, countries having already adopted ASAQ as first-line treatment for uncomplicated malaria. The results of these surveys provide the groundwork for evidence-based policy implementation of ACTs, which could be translated to other countries with similar socio-demographic and malaria profiles. |
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License